Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accounts Payables (2016 - 2025)

Ani Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $62.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 37.08% year-over-year to $62.6 million; the TTM value through Dec 2025 reached $62.6 million, up 37.08%, while the annual FY2025 figure was $62.6 million, 37.08% up from the prior year.
  • Accounts Payables for Q4 2025 was $62.6 million at Ani Pharmaceuticals, down from $69.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $69.8 million in Q3 2025 and bottomed at $11.5 million in Q3 2021.
  • The 5-year median for Accounts Payables is $33.4 million (2023), against an average of $36.8 million.
  • The largest annual shift saw Accounts Payables fell 14.47% in 2021 before it surged 113.0% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $23.0 million in 2021, then increased by 27.6% to $29.3 million in 2022, then grew by 25.18% to $36.7 million in 2023, then increased by 24.46% to $45.7 million in 2024, then surged by 37.08% to $62.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Accounts Payables are $62.6 million (Q4 2025), $69.8 million (Q3 2025), and $54.6 million (Q2 2025).